Curasight doses first patient in Phase 1 study for brain tumor treatment

Publicerat: 2025-12-18 17:28:17

Detta är en nyhet från nyhetsbyrån Finwire Disclaimer

Finwire om Curasight A/S: Curasight doses first patient in Phase 1 study for brain tumor treatment

The research company Curasight has dosed the first patient in a Phase 1 study with uTREAT for aggressive brain tumor. This is stated in a press release.The study concerns patients with glioblastoma.

Läs mer om Curasight A/S